Cite
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
MLA
Uemura, Hiroji, et al. “Safety and Efficacy of Radium-223 Dichloride in Japanese Patients with Castration-Resistant Prostate Cancer and Bone Metastases.” International Journal of Clinical Oncology, vol. 22, no. 5, Oct. 2017, pp. 954–63. EBSCOhost, https://doi.org/10.1007/s10147-017-1130-1.
APA
Uemura, H., Uemura, H., Matsubara, N., Kinuya, S., Hosono, M., Yajima, Y., & Doi, T. (2017). Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. International Journal of Clinical Oncology, 22(5), 954–963. https://doi.org/10.1007/s10147-017-1130-1
Chicago
Uemura, Hiroji, Hirotsugu Uemura, Nobuaki Matsubara, Seigo Kinuya, Makoto Hosono, Yoko Yajima, and Toshihiko Doi. 2017. “Safety and Efficacy of Radium-223 Dichloride in Japanese Patients with Castration-Resistant Prostate Cancer and Bone Metastases.” International Journal of Clinical Oncology 22 (5): 954–63. doi:10.1007/s10147-017-1130-1.